Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2016

13.10.2016 | Original Article

Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia

verfasst von: Savitha Varatharajan, John C. Panetta, Ajay Abraham, Sreeja Karathedath, Ezhilpavai Mohanan, Kavitha M. Lakshmi, Nancy Arthur, Vivi M. Srivastava, Sandeep Nemani, Biju George, Alok Srivastava, Vikram Mathews, Poonkuzhali Balasubramanian

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapy drug resistance and relapse of the disease have been the major factors limiting the success of acute myeloid leukemia (AML) therapy. Several factors, including the pharmacokinetics (PK) of Cytarabine (Ara-C) and Daunorubicin (Dnr), could contribute to difference in treatment outcome in AML.

Methods

In the present study, we evaluated the plasma PK of Dnr, the influence of genetic polymorphisms of genes involved in transport and metabolism of Dnr on the PK, and also the influence of these factors on clinical outcome. Plasma levels of Dnr and its major metabolite, Daunorubicinol (DOL), were available in 70 adult de novo AML patients. PK parameters (Area under curve (AUC) and clearance (CL)) of Dnr and DOL were calculated using nonlinear mixed-effects modeling analysis performed with Monolix. Genetic variants in ABCB1ABCG2, CBR1, and CBR3 genes as well as RNA expression of CBR1, ABCB1, and ABCG2 were compared with Dnr PK parameters.

Results

The AUC and CL of Dnr and DOL showed wide inter-individual variation. Patients with an exon1 variant of rs25678 in CBR1 had significantly higher plasma Dnr AUC [p = 0.05] compared to patients with wild type. Patients who achieved complete remission (CR) had significantly lower plasma Dnr AUC, Cmax, and higher CL compared to patients who did not achieve CR.

Conclusion

Further validation of these findings in a larger cohort of AML patients is warranted before establishing a therapeutic window for plasma Dnr levels and targeted dose adjustment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474CrossRefPubMed Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474CrossRefPubMed
3.
Zurück zum Zitat Kokenberg E, Sonneveld P, Sizoo W, Hagenbeek A, Löwenberg B (1988) Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 6(5):802–812 Kokenberg E, Sonneveld P, Sizoo W, Hagenbeek A, Löwenberg B (1988) Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 6(5):802–812
4.
Zurück zum Zitat Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C (1987) Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol 20(4):311–315PubMed Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C (1987) Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol 20(4):311–315PubMed
5.
Zurück zum Zitat Greene W, Huffman D, Wiernik PH, Schimpff S, Benjamin R, Bachur N (1972) High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity. Cancer 30(6):1419–1427CrossRefPubMed Greene W, Huffman D, Wiernik PH, Schimpff S, Benjamin R, Bachur N (1972) High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity. Cancer 30(6):1419–1427CrossRefPubMed
6.
Zurück zum Zitat Trillet V, Lakhal M, Lang J, Perrin-Fayolle E, Timour Chah Q, Fière D et al (1985) Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate. Eur J Clin Pharmacol 29(1):127–129CrossRefPubMed Trillet V, Lakhal M, Lang J, Perrin-Fayolle E, Timour Chah Q, Fière D et al (1985) Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate. Eur J Clin Pharmacol 29(1):127–129CrossRefPubMed
7.
Zurück zum Zitat Hempel G, Relling MV, de Rossi G, Stary J, De Lorenzo P, Valsecchi MG et al (2010) Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 54(3):355–360CrossRefPubMed Hempel G, Relling MV, de Rossi G, Stary J, De Lorenzo P, Valsecchi MG et al (2010) Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 54(3):355–360CrossRefPubMed
8.
Zurück zum Zitat Hempel G, Reinhardt D, Creutzig U, Boos J (2003) Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 56(4):370–377CrossRefPubMedPubMedCentral Hempel G, Reinhardt D, Creutzig U, Boos J (2003) Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 56(4):370–377CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bogason A, Quartino AL, Lafolie P, Masquelier M, Karlsson MO, Paul C et al (2011) Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. Br J Clin Pharmacol 71(4):514–521CrossRefPubMedPubMedCentral Bogason A, Quartino AL, Lafolie P, Masquelier M, Karlsson MO, Paul C et al (2011) Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. Br J Clin Pharmacol 71(4):514–521CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Krogh-Madsen M, Bender B, Jensen MK, Nielsen OJ, Friberg LE, Honoré PH (2012) Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother Pharmacol 69(5):1155–1163CrossRefPubMed Krogh-Madsen M, Bender B, Jensen MK, Nielsen OJ, Friberg LE, Honoré PH (2012) Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother Pharmacol 69(5):1155–1163CrossRefPubMed
11.
Zurück zum Zitat Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M et al (2014) Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol 74(4):831–838CrossRefPubMedPubMedCentral Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M et al (2014) Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol 74(4):831–838CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8):2434–2439CrossRefPubMed Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8):2434–2439CrossRefPubMed
13.
Zurück zum Zitat Parihar M, Kumar JA, Sitaram U, Balasubramanian P, Abraham A, Viswabandya A et al (2012) Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leuk Lymphoma 53(1):103–109CrossRefPubMed Parihar M, Kumar JA, Sitaram U, Balasubramanian P, Abraham A, Viswabandya A et al (2012) Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leuk Lymphoma 53(1):103–109CrossRefPubMed
14.
Zurück zum Zitat Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P et al (2010) The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genet Cytogenet 203(2):297–302CrossRefPubMed Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P et al (2010) The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genet Cytogenet 203(2):297–302CrossRefPubMed
15.
Zurück zum Zitat Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C et al (1999) An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther Drug Monit 21(3):367–375CrossRefPubMed Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C et al (1999) An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther Drug Monit 21(3):367–375CrossRefPubMed
16.
Zurück zum Zitat Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A et al (2012) Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol 68(12):1577–1586CrossRefPubMed Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A et al (2012) Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol 68(12):1577–1586CrossRefPubMed
17.
Zurück zum Zitat Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69(3):169–174CrossRefPubMed Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69(3):169–174CrossRefPubMed
18.
Zurück zum Zitat Cheson BD (2004) Overview of the revised response criteria for acute myelogenous leukemia. Clin Adv Hematol Oncol HO 2(5):277–279 Cheson BD (2004) Overview of the revised response criteria for acute myelogenous leukemia. Clin Adv Hematol Oncol HO 2(5):277–279
19.
Zurück zum Zitat Galettis P, Boutagy J, Ma DD (1994) Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br J Cancer 70(2):324–329CrossRefPubMedPubMedCentral Galettis P, Boutagy J, Ma DD (1994) Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br J Cancer 70(2):324–329CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Plebuch M, Soldan M, Hungerer C, Koch L, Maser E (2007) Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 255(1):49–56CrossRefPubMed Plebuch M, Soldan M, Hungerer C, Koch L, Maser E (2007) Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 255(1):49–56CrossRefPubMed
21.
Zurück zum Zitat Hintzpeter J, Hornung J, Ebert B, Martin H-J, Maser E (2015) Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase–Carbonyl reductase 1. Chem Biol Interact 5(234):162–168CrossRef Hintzpeter J, Hornung J, Ebert B, Martin H-J, Maser E (2015) Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase–Carbonyl reductase 1. Chem Biol Interact 5(234):162–168CrossRef
22.
Zurück zum Zitat Tak E, Lee S, Lee J, Rashid MA, Kim YW, Park J-H et al (2011) Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol 54(2):328–339CrossRefPubMed Tak E, Lee S, Lee J, Rashid MA, Kim YW, Park J-H et al (2011) Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol 54(2):328–339CrossRefPubMed
23.
Zurück zum Zitat Jang M, Kim Y, Won H, Lim S, Jyothi KR, Dashdorj A et al (2012) Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res 72(16):4214–4224CrossRefPubMed Jang M, Kim Y, Won H, Lim S, Jyothi KR, Dashdorj A et al (2012) Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res 72(16):4214–4224CrossRefPubMed
24.
Zurück zum Zitat Oppermann UC, Maser E (2000) Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144(1–3):71–81CrossRefPubMed Oppermann UC, Maser E (2000) Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144(1–3):71–81CrossRefPubMed
25.
Zurück zum Zitat Lal S, Sandanaraj E, Wong ZW, Ang PCS, Wong NS, Lee EJD et al (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99(10):2045–2054PubMed Lal S, Sandanaraj E, Wong ZW, Ang PCS, Wong NS, Lee EJD et al (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99(10):2045–2054PubMed
26.
Zurück zum Zitat Kalabus JL, Cheng Q, Blanco JG (2012) MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024. PLoS ONE 7(11):e48622CrossRefPubMedPubMedCentral Kalabus JL, Cheng Q, Blanco JG (2012) MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024. PLoS ONE 7(11):e48622CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW (2010) Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332(3):755–763CrossRefPubMed Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW (2010) Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332(3):755–763CrossRefPubMed
28.
Zurück zum Zitat Fan L, Goh B-C, Wong C-I, Sukri N, Lim S-E, Tan S-H et al (2008) Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 18(7):621–631CrossRefPubMed Fan L, Goh B-C, Wong C-I, Sukri N, Lim S-E, Tan S-H et al (2008) Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 18(7):621–631CrossRefPubMed
29.
Zurück zum Zitat Bruhn O, Cascorbi I (2014) Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 10(10):1337–1354CrossRefPubMed Bruhn O, Cascorbi I (2014) Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 10(10):1337–1354CrossRefPubMed
30.
Zurück zum Zitat Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6(2):115–138CrossRefPubMed Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6(2):115–138CrossRefPubMed
31.
Zurück zum Zitat Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T et al (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance. Mol Cancer Ther 1(8):611–616PubMed Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T et al (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance. Mol Cancer Ther 1(8):611–616PubMed
32.
Zurück zum Zitat Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K et al (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56(2):161–172CrossRefPubMed Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K et al (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56(2):161–172CrossRefPubMed
33.
Zurück zum Zitat Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PCS, Lee EJD et al (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99(4):816–823CrossRefPubMed Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PCS, Lee EJD et al (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99(4):816–823CrossRefPubMed
Metadaten
Titel
Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia
verfasst von
Savitha Varatharajan
John C. Panetta
Ajay Abraham
Sreeja Karathedath
Ezhilpavai Mohanan
Kavitha M. Lakshmi
Nancy Arthur
Vivi M. Srivastava
Sandeep Nemani
Biju George
Alok Srivastava
Vikram Mathews
Poonkuzhali Balasubramanian
Publikationsdatum
13.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3166-8

Weitere Artikel der Ausgabe 5/2016

Cancer Chemotherapy and Pharmacology 5/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.